Anticancer Conjugates and Cocktails Based on Methotrexate and Nucleoside Synergism
Anthony R. Vortherms, Hester N. Dang and Robert P. Doyle
Department of Chemistry, Syracuse University, Syracuse, NY 13244-4100, U.S.A.
Abstract
Conjugates of methotrexate (MTX) and the nucleoside analogs 3-azidodeoxythymidine (AZT), iododeoxyuridine (IUdR) and dideoxycytidine (ddC) linked using poly(ethyleneglycol) are presented. In vitro cytotoxicity assays of the conjugates against drug resistant ovarian cell line A2780/AD are preformed and comparisons made to such assays performed for unconjugated (cocktail) systems. All systems tested were inactive, or had low activity, at 24 h. After 72 hr incubation however, the cocktails of MTX and AZT, IUdR or ddC showed high cytotoxicity in the low nanomolar range. The conjugates were only very moderately active with IC50 values in the [0.1 to 1.0 mM] range. Conjugation of the antifolate to the nucleoside analogs has it seems reduced the activity significantly when compared to a cocktail of the components, indicating a conjugate approach is unlikely to translate into success in vivo. The positive note comes from the observation that by combining two of the new conjugates, namely those based on MTX with IUdR or AZT, an IC50 at 24 hours of ∼ [180 μM] was produced.
Readers of this also read:
- Hospital Costs of Colorectal Cancer Care
- Anticancer Conjugates and Cocktails Based on Methotrexate and Nucleoside Synergism
- Glioblastoma Multiforme Oncogenomics and Signaling Pathways
- Treatment of Advanced Non Small Cell Lung Cancer in Routine Care: A Retrospective Analysis of 212 Consecutive Patients Treated in a Community Based Oncology Group Practice
- Photodynamic Diagnosis For Superficial Bladder Cancer: do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results?